Regulation of cellular bioenergetics by hydrogen sulfide
Regulation of cellular bioenergetics by hydrogen sulfide
批准号:
8989546
负责人:
CSABA SZABO
金额:
$29.45万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2017-12-31
关键词:
3-Mercaptopyruvate sulfurtransferaseAcidosisAffectAnabolismAttentionBioenergeticsBiologicalBiological ProcessBiologyBlood VesselsBlood flowBlood specimenCell physiologyCellsCharacteristicsClinicalComplexCritical IllnessDataDevelopmentDiseaseDoseElectron TransportElectronsEnzymesEquilibriumEtiologyFormulationGasesGlycolysisGoalsHealthHemorrhagic ShockHomeostasisHydrogen SulfideHypoxiaIn VitroInjuryIntensive Care UnitsInvestigationInvestigational TherapiesIschemiaLeadLeukocytesLifeLinkMeasurementMeasuresMediatingMediator of activation proteinMedicalMedicineMetabolicMetabolismMitochondriaModelingMolecularMultiple Organ FailureNitrogenOrganOrgan failureOxidation-ReductionOxidative PhosphorylationOxygenPathogenesisPatientsPhysiologicalPhysiologyPlayProcessProductionRegional Blood FlowRegulationRestRoleSeptic ShockShapesShockSmell PerceptionSupplementationTestingTherapeuticTissuesVascular DiseasesWorkbasecell growth regulationcomplex IVcytotoxicdesigneggin vitro Modelin vivoinhibitor/antagonistmetabolic phenotypemitochondrial dysfunctionmouse modelnovelnovel strategiesoxygen transportperipheral bloodphosphodiesterase Vresponse
中文摘要
描述(由申请人提供):我们最近发现了气体生物介质硫化氢(H2S)的基本生物调控机制。首先,我们发现线粒体内H2S生成过程由3-巯基丙酮酸硫转移酶(3-MST)驱动,产生生理量的H2S,从而驱动和平衡氧化磷酸化并维持细胞生物能量。接下来,我们还发现H2S介导的生物能量功能遵循钟形剂量反应,其中低(内源性)H2S水平支持细胞能量,而高水平H2S则具有抑制和有害作用。此外,我们最近已经证明H2S在血管张力的调节中起着关键作用,至少部分是通过
英文摘要
DESCRIPTION (provided by applicant): We have recently discovered fundamental biological regulatory mechanisms of the gaseous biological mediator hydrogen sulfide (H2S). First and foremost, we have discovered that an intramitochondrial H2S generating process, driven by the enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) produces H2S in physiological amounts, which, in term, drives and balances oxidative phosphorylation and maintains cellular bioenergetics. Next, we have also discovered that H2S-mediated bioenergetic functions follow a bell-shaped dose-response, where low (endogenous) levels of H2S support cellular energetics, while high levels of H2S become inhibitory and deleterious. In addition, we have recently demonstrated that H2S plays a critical role in the regulation of vascular tone, at least in part by
acting as a physiological (endogenous) inhibitor of vascular phosphodiesterase 5 (PDE5). Regulation of blood flow and oxygen delivery to tissues is a critical determinant of cellular metabolism; hence, the in vivo bioenergetic role of H2S is the consequence of a combination of its effects on regional blood flow and its direct regulatory actions on cellular energetic processe (oxidative phosphorylation, glycolysis). The first overall goal of the current project is to characterize the bioenergetic roles of H2S in vitro and in vivo. These processes are likely to play
important regulatory roles in normal physiology. In addition, the second goal of the project is to characterize the bioenergetic roles of H2S in selected models of critical illness (circulatory shoc of various etiologies). This second overall goal is guided by the clinical need for novel approaches for the experimental therapy of circulatory shock, as well as by preliminary data demonstrating that there are marked alterations in H2S homeostasis in critical illness. Our investigations will delineate the role of (a) changes in the expression of H2S-producing enzymes; (b) changes in redox status and reactive oxygen/nitrogen species and (c) changes in the degree of tissue hypoxia/acidosis in the biological functions of H2S in circulatory shock. Our project will culminate in the formulation of a unifying concept that will resolve current controversies in the field, and will define the key molecular determinants, which render the metabolic and vascular effects of H2S beneficial vs. detrimental in circulatory shock. In Aim 1, we will determine the regulation of mitochondrial function and cellular bioenergetics by H2S under resting in vitro conditions, as well as during conditions, when various relevant metabolic aspects of circulatory shock are modeled in vitro. In Aim 2, we will determine the role of H2S imbalance in the regulation of vascular tone during circulatory shock. In Aim 3, we will define the
molecular mechanisms by which H2S imbalance contributes to the development of multiple organ failure in murine models of circulatory shock. Finally, in Aim 4, we will investigate the rol of H2S in changes in cellular bioenergetics in leukocytes from patients with circulatory shock ex vivo. These studies are fundamentally relevant for both the field of bioenergetics, as well as for the pathogenesis of critical illness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
-
批准号:9251701
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2017
-
负责人:CSABA SZABO
-
依托单位:
Inhibition of Bacterial and Host-Derived H2S Production for the Therapeutic Enhancement of Anti-Bacterial Host Defense
-
批准号:9245424
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2016
-
负责人:CSABA SZABO
-
依托单位:
Poly(ADP-ribose) synthetase inhibition and diabetes
-
批准号:6582906
-
项目类别:
-
资助金额:$19.98万
-
财政年份:2004
-
负责人:CSABA SZABO
-
依托单位:
Mechanisms of cardiovascular dysfunction in diabetes
-
批准号:7149104
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
Mechanisms of cardiovascular dysfunction in diabetes
-
批准号:6541371
-
项目类别:
-
资助金额:$40.54万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
Doxorubicin cardiotoxicity:protection by peroxynitrite
-
批准号:6691686
-
项目类别:
-
资助金额:$17.48万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
Doxorubicin cardiotoxicity:protection by peroxynitrite
-
批准号:6548807
-
项目类别:
-
资助金额:$5.89万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
Mechanisms of cardiovascular dysfunction in diabetes
-
批准号:6654911
-
项目类别:
-
资助金额:$41.17万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
Mechanisms of cardiovascular dysfunction in diabetes
-
批准号:6784056
-
项目类别:
-
资助金额:$41.81万
-
财政年份:2002
-
负责人:CSABA SZABO
-
依托单位:
(ADP-ribose) synthetase inhibitor for multiple sclerosis
-
批准号:6403320
-
项目类别:
-
资助金额:$21.55万
-
财政年份:2001
-
负责人:CSABA SZABO
-
依托单位:
Novel antioxidants for periodontal disease
-
批准号:6582323
-
项目类别:
-
资助金额:$96.19万
-
财政年份:2000
-
负责人:CSABA SZABO
-
依托单位:
PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK
-
批准号:6294765
-
项目类别:
-
资助金额:$87.68万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
POLY (ADP RIBOSE) SYNTHETASE AND PEROXYNITRITE INDUCED C
-
批准号:6387104
-
项目类别:
-
资助金额:$22.02万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
Adenosine-3 agonists for the suppression of arthritis
-
批准号:6442606
-
项目类别:
-
资助金额:$73.0万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
POLY (ADP RIBOSE) SYNTHETASE AND PEROXYNITRITE INDUCED C
-
批准号:6181517
-
项目类别:
-
资助金额:$21.38万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
Peroxynitrate neutralizing agents for stroke therapy
-
批准号:6482163
-
项目类别:
-
资助金额:$72.88万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
POLY (ADP-RIBOSE) SYNTHETASE AND REPERFUSION INJURY
-
批准号:2857941
-
项目类别:
-
资助金额:$20.31万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
PARS and peroxynitrite induced cell death
-
批准号:7140967
-
项目类别:
-
资助金额:$32.27万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
Peroxynitrate neutralizing agents for stroke therapy
-
批准号:6659048
-
项目类别:
-
资助金额:$95.11万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
POLY RIBOSE SYNTHETASE & ENDOTHELIAL DYSFUNCTION IN IDDM
-
批准号:6185189
-
项目类别:
-
资助金额:$10.43万
-
财政年份:1999
-
负责人:CSABA SZABO
-
依托单位:
国内基金
海外基金
肿瘤微环境因子Lactic acidosis在肿瘤细胞耐受葡萄糖剥夺中的作用机制研究
-
批准号:81301707
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:吴昊
-
依托单位: